Access provision is a key element of the PREVALENT initiative supporting use of state-of-the-art infrastructures providing services for the pre-clinical evaluation of drugs, the validation of animal models for pre-clinical evaluation, and Omics-based (transcriptomics and metabolomics) analyses for the EU and global user community.

The participating infrastructures provide open access to users.

Facilities with services

Czech Centre for Phenogenomics

The Czech Centre for Phenogenomics provides expertise and services to the biomedical research community, which study the function of genes in biological processes and / or human disorders in vivo using mouse or rat models. CCP covers a full spectrum of genetic engineering services, strain cryopreservation and archiving services, advanced phenotyping and imaging services, as well as specific pathogen free (SPF) animal housing and husbandry.

Institut Clinique de la Souris – ICS (Mouse Clinical Institute – MCI)

The ICS is a national infrastructure devoted to translational research and functional genomics. The ICS focuses on understanding the role of genetics in health and disease. It concentrates on global studies of experimental variation of genome sequence in the mouse model. It combines the capacity of generating genetically engineered mouse model on a large scale with a high-throughput and comprehensive phenotypic analysis of the animals. The Institute’s phenotyping platforms are adapted for the study of mutant mice and genetic reference populations but can also be used for preclinical studies including the validation of therapeutic targets as well as pharmacological and toxicological studies in the mouse.

MRC Harwell

MRC Harwell is a leading international centre for mouse genetics and functional genomics and is a lead partner in the International Mouse Phenotyping Consortium (IMPC). MRC Harwell offers a wide range of services for the scientific community. These build upon our extensive experience in mouse functional genomics, from the initial husbandry and breeding of genetically altered lines to the final phenotyping and analysis of the tissues. The services include, but are not limited to, the generation of genetically altered mouse models, access to archived material, husbandry and phenotyping services, gene expression analysis and clinical pathology.

Erasmus Centre for Biomics

ERASMUS MC is operating a genomics core facility and has an outstanding track record of scientific achievement, innovation and successful collaborative work, as well as servicing, as demonstrated in >200 publications. The Centre for Biomics is fully equipped with state-of-the-art research instrumentation for sample preparation and processing for next generation sequencing. The Centre offers a full-blown transcriptomics service from sample to analysed data and supports small and large projects.

BSRC Fleming

BSRC Fleming is a leading Greek research institution, internationally recognized for its contributions to understanding human diseases and development of novel diagnostic and therapeutic tools by generating and studying relevant animal models. Fleming offers an extensive range of state-of-the-art facilities that span the generation of genetically engineered animals to their phenotypic assessment. These include a transgenics & gene targeting facility , an animal house facility, high throughput omics technologies such as genomics and proteomics, flow cytometry, histology and advanced imaging technologies. It also offers CyTOF and a single cell analysis unit as part of an ongoing developing collaboration between Fleming and pMedGR that sets the basis for personalized and stratified drug discovery and development.’

Biomedcode Hellas SA

Biomedcode Hellas SA is a highly innovative Contract Research Organization that supports the Pharma Industry and scientific community offering customized solutions for their drug development projects. Biomedcode combines expertise and scientific consultation in preclinical testing with a unique collection of humanized mouse disease models and advanced technologies, including flow cytometry, histology, molecular assays and imaging, to provide preclinical services evaluating the efficacy of novel and biosimilar human therapeutics targeting Arthritis, Spondyloarthritis, IBD, Osteoporosis, Psoriasis, Multiple Sclerosis and other human pathologies.

News & Events

8th September
Variability in Genome Editing Outcomes Challenges for Research Reproducibility and Clinical Safety
Researchers at MRC Harwell, alongside their colleagues at Université de Strasbourg and Great Ormond Street Institute of Child Health, have published a review in Molecular Therapy ( The review explores the reliability and challenges of genome editing application in both research and in clinic.
Show detail
All news
September 17 – 18, 2020 | Prague, Czech Republic
2nd CCP Phenogenomics Conference 2020
The first day will be devoted to the theme “From chemistry via preclinical pipeline to therapeutics“, which emphasizes the translation of the basic research into the application. The second day is specifically devoted to CCP’s users and cooperation partners working in the field of immunology, hematology, genetic base of diseases, and neurobiology.
Show detail
All events